Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
11/09/2026 17:18
BRIEF-Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB Sept 11 (Reuters) - JCR Pharmaceuticals Co., Ltd. 4552.T:
MEDIPAL HOLDINGS CORPORATION AND JCR PHARMACEUTICALS DOSE FIRST PATIENT IN GLOBAL PHASE I/II TRIAL OF JR-446 FOR MUCOPOLYSACCHARIDOSIS TYPE IIIB
(((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results